International Society of Urological Pathology (ISUP) grade 1 to 3
Localised prostate cancer (N0 and M0 status) (only required for ISUP 3 patients)
1. Newly diagnosed patients: Staging must be performed within 6 months from enrolment into the trial.
2. Active surveillance: N0/M0 at the time of diagnosis and no clinical suspicion of prostate cancer outside the prostatic bed at the time of enrolment into the trial.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Prostate biopsy within 1 to 6 months (patients with a biopsy within the last month are excluded to avoid possible inflammation artefacts on the PET scan)
1. The biopsy can be part of the primary staging, a confirmatory biopsy, or serial biopsy as part of an AS.
2. At least 1 core must be MRI-guided.
You may not be if
Any prior treatment for prostate cancer (surgery, external beam radiation therapy, brachytherapy, hormone therapy, or chemotherapy)
Chronic prostatitis (any signs or symptoms of chronic bacterial prostatitis or chronic pelvic prostatitis and pain syndrome, or known diagnosis of asymptomatic inflammatory prostatitis)
Acute infections within the prostatic bed or lower urinary tract infections
Participants have inadequate bone marrow, kidney, liver, heart, or lung function:
